Associated Papers
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Brehm JH et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2012
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S et al.
Chemmedchem, 2011
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
Ceccherini-Silberstein F et al.
The Journal of Antimicrobial Chemotherapy, 2010
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT et al.
The Journal of Antimicrobial Chemotherapy, 2010
The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
Xu HT et al.
Antimicrobial Agents and Chemotherapy, 2010
Select a paper to view details